Update on the role of modified release mesalamine in the management of ulcerative colitis and Crohn's disease
{{output}}
5-aminosalicyclates (5-ASA) remain a key first-line therapy for patients with ulcerative colitis (UC). A range of 5-ASA preparations is available and Eudragit-S(®) coated modified release formulations of mesalamine, such as Asacol(®), remain among the most p... ...
